SMC Radiation Oncology SABR Cohort for Oligometastasis
Recruiting
Observational Study
Stereotactic Body Radiation Therapy (SBRT)
Oligometastasis
Oligoprogression
ctDNA
Patient-Reported Outcomes (PRO)
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 60 (estimated)
- Sponsor
- Samsung Medical Center · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this observational study is to evaluate the efficacy and safety of stereotactic body radiotherapy (SABR) in patients with oligometastatic or oligoprogressive cancer.
The main questions it aims to answer are:
1. oncologic outcomes (progression-free survival, local failure rate),
2. patient-reported outcomes,
3. physician-assessed toxicity, and
4. dynamics of circulating tumor DNA (ctD…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Performance status (ECOG PS) 0-2
* Diagnosed with metastatic disease
* Confirmed to have oligometastatic/oligoprogressive cancer on imaging performed within 4 weeks (up to 5 lesions)
Exclusion Criteria:
* Patient with a history of prior radiotherapy to the site planned for S…
Contacts